StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report released on Tuesday. The firm issued a sell rating on the stock. Moleculin Biotech Price Performance Shares of Moleculin Biotech stock opened at $0.43 on Tuesday. The stock has a market capitalization of $12.74 million, a price-to-earnings ratio of -0.42 […]
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including.
– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company s Annamycin clinical trials
– Next generation anthracycline,.
Form 8-K Moleculin Biotech, Inc For: Sep 18 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 38,100 shares, a drop of 75.4% from the August 15th total of 155,100 shares. Based on an average daily volume of 164,900 shares, the short-interest ratio […]